ANIK
Anika Therapeutics, Inc.
ANIK lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
ANIK Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Stable | |
| Strong |
ANIK's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is under pressure.
ANIK PE Valuation
ANIK has no meaningful PE right now: it lost money over the past year.
ANIK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ANIK, with profitability improving.
ANIK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.91 | — |
| Q3 2026 | -$0.13 | +$2.15 |
| Q2 2026 | -$0.27 | +$3.88 |
| Q1 2026 | -$0.79 | +$3.09 |
| Q4 2025 | -$0.76 | +$3.09 |
| Q3 2025 | -$2.28 | +$4.36 |
| Q2 2025 | -$4.15 | +$0.91 |
| Q1 2025 | -$3.88 | +$1.36 |
| Q4 2024 | -$3.85 | +$1.79 |
ANIK is still losing money, but far less than before: $0.13 per share over the past year, against $6.64 at its worst in late 2024.
ANIK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30.6M | +10% |
| Q2 2026 | $32.6M | +16% |
| Q1 2026 | $29.6M | +13% |
| Q3 2025 | $27.8M | -28% |
| Q2 2025 | $28.2M | -33% |
| Q1 2025 | $26.2M | -35% |
| Q3 2024 | $38.8M | -6.5% |
| Q2 2024 | $41.9M | -5.4% |
ANIK's revenue is recovering but still below its 2023 peak: $31M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.3% | -35 points |
| Q2 2026 | 9.1% | +24 points |
| Q1 2026 | -19% | -2.2 points |
| Q4 2025 | 2.1% | N/A |
| Q3 2025 | 32% | +105 points |
| Q2 2025 | -15% | -15 points |
| Q1 2025 | -16% | -3.9 points |
| Q3 2024 | -72% | -54 points |
ANIK's operating margin was −2.3% last quarter, down 35 points from the same quarter a year ago.
ANIK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.7M | +35% |
| Q2 2026 | -$2.1M | -$477K |
| Q1 2026 | -$6.3M | -$3.3M |
| Q4 2025 | $4M | +1351% |
| Q3 2025 | $5M | +31% |
| Q2 2025 | -$1.7M | +$2.8M |
| Q1 2025 | -$3M | -$1M |
| Q4 2024 | $275K | -85% |
ANIK still generates free cash flow, though less than at its 2019 peak: $2M over the past year.
ANIK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -14.7x | Net Cash |
| Q2 2026 | -3.0x | Net Cash |
| Q1 2026 | -7.6x | Net Cash |
| Q4 2025 | -8.8x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q1 2022 | -36.9x | Net Cash |
| Q4 2021 | -10.4x | Net Cash |
| Q3 2021 | -45.8x | Net Cash |
ANIK has more cash than debt.
ANIK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 29.4 | Neutral |
ANIK's weekly RSI is 36 (neutral) and its Stochastic is 29 (neutral).
ANIK PE vs Healthcare Sector
| Metric | ANIK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ANIK has no meaningful PE right now: it lost money over the past year.
ANIK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.7 | 26% below |
| 20 week MA | $18.9 | 27% below |
| 50 week MA | $15.2 | 9% below |
| 100 week MA | $13.8 | 0.1% above |
| 200 week MA | $19.0 | 27% below |
ANIK's trend is mixed: it's above one of its five weekly moving averages, and 27% below its 200-week average.
ANIK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $52.8 | $43.2 | -18% |
| 2021 | $43.2 | $38.0 | -12% |
| 2022 | $38.0 | $27.9 | -27% |
| 2023 | $27.9 | $22.7 | -19% |
| 2024 | $22.7 | $16.2 | -28% |
| 2025 | $16.2 | $9.55 | -41% |
| 2026 YTD | $9.55 | $13.8 | +45% |
ANIK has finished every year since 2020 lower, and it's up 45% so far in 2026.